佛慈制药
(002644)
| 流通市值：37.48亿 | | | 总市值：37.48亿 |
| 流通股本：5.11亿 | | | 总股本：5.11亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 274,329,503.97 | 1,163,134,313.96 | 860,511,173.37 | 609,032,829.06 |
| 营业收入 | 274,329,503.97 | 1,163,134,313.96 | 860,511,173.37 | 609,032,829.06 |
| 二、营业总成本 | 245,785,793.53 | 1,079,170,441.49 | 804,026,862.62 | 553,607,294.29 |
| 营业成本 | 189,023,844.72 | 801,838,651.18 | 611,854,747.79 | 417,753,406.77 |
| 税金及附加 | 3,569,146.32 | 13,360,205.31 | 9,343,710.1 | 6,384,202.45 |
| 销售费用 | 27,980,563.19 | 153,728,332.34 | 106,840,690.98 | 77,949,445.64 |
| 管理费用 | 18,774,078.11 | 84,291,270.17 | 59,010,185.88 | 39,284,801.34 |
| 研发费用 | 6,885,069 | 30,926,615.07 | 21,266,535.43 | 14,909,087.27 |
| 财务费用 | -446,907.81 | -4,974,632.58 | -4,289,007.56 | -2,673,649.18 |
| 其中:利息费用 | - | 1,240,745.92 | - | 669,350.8 |
| 其中:利息收入 | - | 5,369,355.9 | - | 3,524,000.36 |
| 加:投资收益 | -2,609,200 | -4,491,521.21 | 1,192,877.25 | 1,462,701.19 |
| 资产处置收益 | 175.71 | - | - | - |
| 资产减值损失(新) | 0 | -1,057,703.13 | 220,642.55 | 227,139.42 |
| 信用减值损失(新) | -7,997,050.08 | -14,638,388.83 | 3,386,465.89 | 3,476,730.97 |
| 其他收益 | 5,061,682.57 | 19,498,580.25 | 13,962,631.17 | 9,393,999.35 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 22,999,318.64 | 83,274,839.55 | 75,246,927.61 | 69,986,105.7 |
| 加:营业外收入 | 4,222.26 | 116,415.15 | 64,640.52 | 58,233.84 |
| 减:营业外支出 | 400,834.8 | 1,749,481.98 | 1,017,518.94 | 1,011,608.19 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 22,602,706.1 | 81,641,772.72 | 74,294,049.19 | 69,032,731.35 |
| 减:所得税费用 | 3,961,129.93 | 13,519,775.04 | 15,259,514.05 | 12,189,841.5 |
| 六、净利润 | 18,641,576.17 | 68,121,997.68 | 59,034,535.14 | 56,842,889.85 |
| 持续经营净利润 | 18,641,576.17 | 68,121,997.68 | 59,034,535.14 | 56,842,889.85 |
| 归属于母公司股东的净利润 | 18,387,224.27 | 67,189,706.97 | 59,119,316.28 | 57,053,385.37 |
| 少数股东损益 | 254,351.9 | 932,290.71 | -84,781.14 | -210,495.52 |
| (一)基本每股收益 | 0.04 | 0.13 | 0.12 | 0.11 |
| (二)稀释每股收益 | 0.04 | 0.13 | 0.12 | 0.11 |
| 八、其他综合收益 | - | -241,981.88 | 38,506.71 | 47,816.37 |
| 归属于母公司股东的其他综合收益 | - | -132,333.84 | 21,058.36 | 26,149.58 |
| 九、综合收益总额 | 18,641,576.17 | 67,880,015.8 | 59,073,041.85 | 56,890,706.22 |
| 归属于母公司股东的综合收益总额 | 18,387,224.27 | 67,057,373.13 | 59,140,374.64 | 57,079,534.95 |
| 归属于少数股东的综合收益总额 | 254,351.9 | 822,642.67 | -67,332.79 | -188,828.73 |
| 公告日期 | 2024-04-10 | 2024-04-10 | 2023-10-31 | 2023-08-03 |
| 审计意见(境内) | | 标准无保留意见 | | |